These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 28273994)

  • 1. A Report of Successful Procedural, Clinical, and Angiographic Outcomes with a Tapered Stent of a Patient in Naturally Tapered Coronary Vessel.
    Premchand RK; Kumar YS
    J Clin Diagn Res; 2017 Jan; 11(1):OD06-OD07. PubMed ID: 28273994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of BioMime Morph stent in treating left main triple vessel disease: a case report.
    Sharma YP; Santosh K; Panda P; Prasad K; Uppal L; Y S S; Pruthvi CR; Dinakar B
    Egypt Heart J; 2020 Aug; 72(1):47. PubMed ID: 32754802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes of novel BioMime Morph tapered stent in long and multiple coronary artery lesions.
    Sharma YP; Uppal L; Panda P; Mohanty S; Kasinadhuni G; Krishnappa D; Mehrotra S; Gupta A; Prasad K; Santosh K; Bootla D; Ghosh S
    Anatol J Cardiol; 2021 Dec; 25(12):896-901. PubMed ID: 34866584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus drug-eluting stent.
    Podolec J; Skubera M; Niewiara Ł; Podolec M; Pieniążek P; Bartuś K; Żmudka K; Legutko J
    Postepy Kardiol Interwencyjnej; 2019; 15(1):46-51. PubMed ID: 31043984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Stent Loss and Its Retrieval of a Long, Tapering Morph Stent in a Tortuous, Calcified Lesion.
    Sinha SK; Mahrotra A; Abhishekh NK; Razi M; Aggarwal P; Tripathi S; Rekwaal L; Singh A
    Cardiol Res; 2018 Feb; 9(1):63-67. PubMed ID: 29479390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
    Sawhney N; Moses JW; Leon MB; Kuntz RE; Popma JJ; Bachinsky W; Bass T; DeMaio S; Fry E; Holmes DR; Teirstein PS
    Circulation; 2004 Jul; 110(4):374-9. PubMed ID: 15249503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the meriT-1 trial.
    Dani S; Costa RA; Joshi H; Shah J; Pandya R; Virmani R; Sheiban I; Bhatt S; Abizaid A
    EuroIntervention; 2013 Aug; 9(4):493-500. PubMed ID: 23965355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of Implanting 50-60 mm-Tapered Drug Eluting Stents in Chronic Total Occlusions.
    Miñana G; Consuegra-Sánchez L; Rumiz E; Valero E; García-Blas S; Pernias V; Husser O; Fernández-Cisnal A; Sanchis J; Núñez J
    Cardiovasc Revasc Med; 2019 Dec; 20(12):1117-1122. PubMed ID: 30878362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Performance of BioMime™ Morph Sirolimus-Eluting Coronary Stent System for Very Long Coronary Lesions.
    Patted SV
    Cardiol Res; 2024 Jun; 15(3):169-178. PubMed ID: 38994223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
    Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
    Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance.
    Seung KB; Kim YH; Park DW; Lee BK; Lee CW; Hong MK; Kim PJ; Chung WS; Tahk SJ; Park SW; Park SJ
    J Am Coll Cardiol; 2005 Sep; 46(5):787-92. PubMed ID: 16139126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus-eluting stent treatment for complex proximal left anterior descending artery stenoses: 7-month clinical and angiographic results.
    Khattab AA; Otto A; Toelg R; Geist V; Klatt L; Richardt G
    J Invasive Cardiol; 2005 Nov; 17(11):582-6. PubMed ID: 16264201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proximal left anterior descending coronary artery revascularization with drug-eluting stents.
    Guardado JH; Moreno R; Costa J; Perez-Viscayno MJ; Segura L; Alfonso F; Hernández R; Escaned J; Bañuelos C; Macaya C
    Arq Bras Cardiol; 2007 Feb; 88(2):159-66. PubMed ID: 17384832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents in bifurcation lesions: to stent one branch or both?
    Assali AR; Assa HV; Ben-Dor I; Teplitsky I; Solodky A; Brosh D; Fuchs S; Kornowski R
    Catheter Cardiovasc Interv; 2006 Dec; 68(6):891-6. PubMed ID: 17086532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First report of the use of long-tapered sirolimus-eluting coronary stent for the treatment of chronic total occlusions with the hybrid algorithm.
    Zivelonghi C; van Kuijk JP; Nijenhuis V; Poletti E; Suttorp MJ; van der Heyden JAS; Eefting FD; Rensing BJ; Ten Berg JM; Azzalini L; van den Brink FS; Ribichini F; Colombo A; Henriques JPS; Agostoni P
    Catheter Cardiovasc Interv; 2018 Nov; 92(5):E299-E307. PubMed ID: 29411523
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.